NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Casgevy was approved in record time with CHM’s help.

In CHM’s own annual report, they highlighted their advisory role in the review of Casgevy, along with other noteworthy approvals…
“CHM continued to carefully consider the data on quality, efficacy & safety of a number of new active substances and after detailed deliberations on diverse issues, advised the MHRA on the approvability of …

• Casgevy (exagamglogene autotemcel), a gene therapy product based on innovative gene-editing CRISPR tool for treatment of sickle-cell disease and
transfusion dependent ß-thalassemia, which was approved first in the UK before any other country in the world.”

https://assets.publishing.service.gov.uk/media/687a10f0312ee8a5f0806b56/HMR_Advisory_Bodies_Commission_on_Human_Medicines_Annual_Report_2024.pdf